Agios Pharmaceuticals Inc (NASDAQ:AGIO)

84.05
Delayed Data
As of 4:00pm ET
 -1.61 / -1.88%
Today’s Change
45.11
Today|||52-Week Range
89.33
+47.02%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$4.8B

Company Description

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. Its product candidates include IDHIFA, ivosidenib, AG-881, AG-348, and AG-270. The comany was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Contact Information

Agios Pharmaceuticals, Inc.
88 Sidney Street
Cambridge Massachusetts 02139-4169
P:(617) 649-8600
Investor Relations:
(617) 649-8299

Employees

Shareholders

Mutual fund holders65.70%
Individual stakeholders22.90%
Other institutional16.59%

Top Executives

David Paul SchenkeinPresident, Chief Executive Officer & Director
Andrew J. HirschCFO & Head-Corporate Development
Scott BillerChief Scientific Officer
Chris BowdenChief Medical Officer
Clive PatienceSenior Vice President-Technical Operations